Everything below concerns dose range. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
=== Oceania === 14UD The Australian National University, Canberra, Australia SSAMS The Australian National University, Canberra, Australia ANTARES 10MV, STAR 2MV, Sydney, Australia Rafter Radiocarbon Laboratory, GNS Science, New Zealand Chronos 14Carbon-Cycle Facility, UNSW, Australia.
=== Pharmacodynamics === The actions and effects of nutmeg and its constituents in in-vitro systems and animals have been described and reviewed. Nutmeg constituents like myristicin and elemicin have been reported to interact with serotonin receptors. In a subsequent study however, nutmeg extracts showed no affinity for any of the serotonin receptors nor for various other receptors including the muscarinic acetylcholine receptors among others (all <50% binding inhibition at 10,000 nM). Myristicin has been found to act as a weak monoamine oxidase inhibitor (MAOI). Neither myristicin nor elemicin produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. However, in another study, elemicin did produce the head-twitch response. On the other hand, myristicin failed to produce electroencephalogram (EEG) activation and behavioral effects similar to those of psychedelic amphetamines such as MMDA in animals. Another study also reported that myristicin did not produce amphetamine-like behavioral effects in rodents. Nutmeg extracts were compared to Δ9-tetrahydrocannabinol (Δ9-THC), amphetamine, and morphine in rodents and one extract was found to have various activities including some cannabimimetic-like effects. No affinity for the cannabinoid CB1 and CB2 receptors was found (<50% binding inhibition at 10,000 nM).
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows:
== Comparison of somatostatin receptor agonists and antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had a higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time, and unbound more slowly than the Lu-DOTA-TATE agonist.
Sources: en.wikipedia.org
However, after the East Pakistani Awami League emerged victorious over the Pakistan Peoples Party (PPP), Yahya Khan and the military refused to transfer power. This led to Operation Searchlight, a military crackdown, and eventually sparked the war of liberation by Bengali Mukti Bahini forces in East Pakistan, described in West Pakistan as a civil war rather than a liberation struggle.
=== Absorption and distribution in the body === Following oral administration, alitretinoin exhibits variable absorption, which is increased when taken with food. It is extensively bound to plasma proteins. Metabolism occurs in the liver via CYP3A4, forming 4-oxoalitretinoin. The half-life ranges from 2 to 10 hours, and elimination occurs primarily renally. No significant systemic distribution is observed after dermal application.
=== Lifespan === The lifespan of a starfish varies considerably among species. For example, Leptasterias hexactis reaches sexual maturity at 20 g (0.7 oz) in two years and lives for about ten years. Pisaster ochraceus matures at 70–90 g (2.5–3.2 oz) in five years and has a maximum recorded lifespan of 34 years.
Sources: en.wikipedia.org
=== Synthesis === Mephedrone can be synthesised in several ways. The simplest method, due to the availability of the compounds, is to add 4-methylpropiophenone dissolved in glacial acetic acid to bromine, creating an oil fraction of 4'-methyl-2-bromopropiophenone. The oil fraction can then be dissolved in dichloromethane (CH2Cl2) and drops of the solution added to another solution of CH2Cl2-containing methylamine hydrochloride and triethylamine. Hydrochloric acid (HCl) is then added and the aqueous layer is removed and turned alkaline using sodium hydroxide before the amine is extracted using CH2Cl2. The CH2Cl2 is then evaporated using a vacuum, creating an oil which is then dissolved in a nonaqueous ether. Finally, HCl gas is bubbled through the mixture to produce 4-methylmethcathinone hydrochloride. This method produces a mixture of both enantiomers and requires similar knowledge to that required to synthesise amphetamines and MDMA.
Prior to this, there had been failed synthesis attempts in 1986–87 at the Joint Institute for Nuclear Research in Dubna (then in the Soviet Union) and in 1990 at the GSI. A 1995 attempt at the Lawrence Berkeley National Laboratory resulted in signs suggesting but not pointing conclusively at the discovery of a new isotope 267Ds formed in the bombardment of 209Bi with 59Co, and a similarly inconclusive 1994 attempt at the JINR showed signs of 273Ds being produced from 244Pu and 34S. Each team proposed its own name for element 110: the American team proposed hahnium after Otto Hahn in an attempt to resolve the controversy of naming element 105 (which they had long been suggesting this name for), the Russian team proposed becquerelium after Henri Becquerel, and the German team proposed darmstadtium after Darmstadt, the location of their institute. The IUPAC/IUPAP Joint Working Party (JWP) recognised the GSI team as discoverers in their 2001 report, giving them the right to suggest a name for the element.
White blood cells The G-CSF-receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates proliferation and differentiation into mature granulocytes. G-CSF stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. G-CSF regulates them using Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and Ras/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway. Hematopoietic System G-CSF is also a potent inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the bloodstream, although it has been shown that it does not directly affect the hematopoietic progenitors that are mobilized. Neurons G-CSF can also act on neuronal cells as a neurotrophic factor. Indeed, its receptor is expressed by neurons in the brain and spinal cord. The action of G-CSF in the central nervous system is to induce neurogenesis, to increase the neuroplasticity and to counteract apoptosis. These properties are currently under investigations for the development of treatments of neurological diseases such as cerebral ischemia.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.